BioPharma Dive March 18, 2025
Forth Therapeutics, Signadori Bio and BioClec announced investments from the European venture capital firm as part of its new €165 million “Biovelocita” fund.
European life sciences investor Sofinnova Partners on Tuesday closed a new biotechnology-focused fund, raising €165 million euros, or more than $180 million, to help young drugmakers advance new medicines.
Called Biovelocita II, the fund was backed by major pharmaceutical companies Amgen and Bristol Myers Squibb as well as Pfizer Ventures.
At least three new startups have already been launched out of the fund: U.K.-based Forth Therapeutics, French biotech Signadori Bio and Italy’s BioClec. None of the companies disclosed how much funding they individually received.
Forth is developing treatments for fibrosis based on research from the lab of...
Today's Sponsors
Today's Sponsor